Hepatitis B ‘functionally cured’ in nearly one in five
Chronic hepatitis B infects 250 to 300 million people worldwide and kills one million every year. The standard treatment cures fewer than one in a hundred.
Hepatitis B is a viral infection that can chronically damage the liver, leading to cirrhosis and liver cancer. Existing drugs, known as nucleoside analogues, suppress viral replication but rarely eliminate the virus. A functional cure, where the immune system suppresses the virus to undetectable levels, occurs in only around one percent of patients on current standard treatment.
Clinical trial data presented by GSK paint a fundamentally different picture. The study shows that nearly twenty percent of participants achieved a functional cure after treatment with the experimental compound. That is twenty times the effectiveness of the current standard.
What a functional cure means
A functional cure for hepatitis B means that a specific viral surface protein called HBsAg is no longer detectable in the blood, and that the immune system has produced antibodies capable of preventing the virus from rebounding. The virus is not necessarily gone from the body entirely, but the infection is controlled in a way that protects the liver from further damage.
Exactly how the new compound achieves this has not been fully disclosed in publicly available summaries. GSK has kept the mechanistic details largely undisclosed at this stage. The results concern a subset of trial participants and the full study is ongoing.
Why this matters for longevity
Chronic liver disease accelerates biological aging at the organ level. Cirrhosis and liver cancer, both consequences of long-term hepatitis B infection, significantly shorten lifespan. An effective treatment removes that disease burden. For the 250 to 300 million people living with chronic infection worldwide, a drug with this profile would represent one of the largest infectious disease advances in years.
The data are preliminary and have not yet been published in a peer-reviewed journal. Larger trials will need to confirm safety and efficacy at scale.